Akebia Therapeutics Inc (AKBA) Implied Volatility Current

Tracking AKBA implied volatility helps you identify when options premiums on Akebia Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Akebia Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when AKBA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Akebia Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For AKBA, tracking metrics like AKBA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on AKBA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where AKBA implied volatility sits today versus where it has been. Our scanner ranks Akebia Therapeutics Inc implied volatility against its historical range, surfaces extremes in AKBA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Akebia Therapeutics Inc IV is rich or cheap — measure it, then act on it.